Latest Market Access News

Variscan Mines Limited is advancing its high-grade zinc projects in Spain with a near-term production target and strategic expansion into Ireland, supported by strong drilling results and favorable market conditions.

Admiralty Resources has secured a pivotal contract with global trader Trafigura to market its Mariposa Iron Ore, marking a key step towards commercial production and revenue generation.

BTC Health has raised $2 million through a share placement priced at a slight premium, with director Martin Kahanovitz participating and a new South African investor joining the register.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

PC Gold has secured a dual listing on the Frankfurt Stock Exchange, opening new doors to European investors as it advances its Spring Hill Gold Project in Australia’s Northern Territory.

Capricorn Metals Ltd’s CMMO securities have been reinstated to trading on the ASX after meeting compliance requirements, signaling renewed market activity. Investors will be watching closely to gauge the impact on liquidity and price movement.

Pinnacle Minerals has begun trading on the U.S. OTCQB market under ticker PIMLF, enhancing access for American investors and supporting its strategic growth in critical minerals projects across Idaho and Washington.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in FSGS kidney disease has passed its seventh Independent Data Monitoring Committee review with no safety concerns, reinforcing the drug’s promising safety profile.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Australian Bond Exchange narrowed its FY25 loss by 26% through disciplined cost cuts and is advancing its fintech strategy with AI-driven credit tools and tokenised asset ambitions.